Cetuximab · Pharmaceutical drug · YYNN

Cetuximab

? TBD

Pharmaceutical drug

Ratings
0

Nobody has rated this yet. Be the first!

Subject of
5

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

scientific article

Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial

scientific article published on 22 July 2019

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

scientific article

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab

scientific article

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

scientific article

Lists
0

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.

Instance of

type of chemical entity

Subclass of

Chemical compound

Wikidata